Publication Topic

Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, DuFour S, et al. 2016. Use of oritavancin in acute bacterial skin and skin structure infection patients receiving intravenous antibiotics: A US hospital budget impact analysis. Clin Drug Investig. 2016 36(2):157-68; doi: 10.1007/s40261-015-0365-8.

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. 2016. Hospitalizations for older patients with acute myeloid leukemia (AML): Inpatient treatment is intensive and costly. Value in Health 19(3):A246; doi: 10.1016/j.jval.2016.03.1051.

Sacks NC, Sharma A, Cyr PL, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. Value in Health 19(7):A611; doi: 10.1016/j.jval.2016.09.1523.

Wu E, Jensen IS, Cyr PL, Fan W, Mitchell M, Sulham K, Nathwani D. Use of oritavancin for the treatment of skin and soft tissue infections: A UK hospital budget impact analysis. ISPOR 20th Annual International Meeting, Philadelphia, PA, 2015.

Jensen I, Halbert R, Giuseppe R, Naoshy S, Iqbal SU, Zhimin X, McSweeney P. 2015. A hospital budget impact model to evaluate plerixafor in stem cell mobilization: Impact of primary research and direct stakeholder engagement. Eur J Hosp Pharm 22(3):142–149; doi: 10.1136/ejhpharm-2014-000543.

Sacks NC, Ash AS, Ghosh K, Rosen AK, Wong JB, Cutler DM, Rosen AB. 2015. Recent national trends in acute myocardial infarction hospitalizations in Medicare: Shrinking declines and growing disparities [Letter to the Editor]. Epidemiol 26(4):e46–47; doi: 10.1097/EDE.0000000000000298.

Sacks NC, Burgess JF, Cabral HJ, McDonnell ME, Pizer SD. 2015. The effects of cost sharing on adherence to medications prescribed for concurrent use: Do definitions matter? J Manag Care Pharmacy 21(8):678–687.

Sacks NC, Ash AS, Ghosh K, Rosen AK, Wong JB, Rosen AB. 2015. Trends in acute myocardial infarction hospitalizations: Are we seeing the whole picture? Am Heart J 170(6):1211-1219; doi: 10.1016/j.ahj.2015.09.009.

Wu C, Fortier KJ, LaPensee K, Fan W, Mitchell M, Cyr PL, Jensen IS. A US hospital economic impact model for oritavancin in ABSSSI patients with risk of MRSA infections. Abstract PSS10, ISPOR 17th Annual European Congress 2014.

Jensen IS, Bay C, Cyr PL. Estimating the impact of combining cangrelor and bivalirudin to a U.S. hospital performing PCI procedures. ISPOR 18^th Annual International Meeting, New Montreal Quebec, 2014.

Pinto DS, Nicholson G, Harrington RA, Cyr PL, Bhatt DL. CHAMPION PHOENIX Study economic results: Direct hospitalization costs of patients receiving clopidogrel or cangralor during percutaneous coronary intervention. American Heart Association QCOR conference, Baltimore, MD, 2014.

Jensen IS, Wu C, Bay CB, Cyr PL. Estimating the clinical value of cangrelor in patients undergoing PCI. International Academy of Cardiology, 19th World Congress on Heart Disease, Boston, MA, 2014.

Wu C, Fortier K, Fan WJ, LePensse K, Bay CB, Cyr PL, Jensen IS. A U.S. hospital budget impact model for oritivancin in ABSSSI patients with risk of MRSA infections. ISPOR 16^th Annual European Congress, Amsterdam, Netherlands, 2014.

Bay C, Cyr PL, Jensen IS. Estimating the value of cangrelor from eliminating preloading in coronary artery bypass graft (CABG) patients. ISPOR 16th Annual European Congress, Amsterdam, Netherlands, 2014.

Jensen IS, Halbert RJ, Thompson SF, Hennessy D, Pacconi S, McSweeney PA. Increased use of plerixafor in patients with multiple myeloma and non-Hodgkin’s lymphoma in the United States: A budgetary impact analysis. Abstract C14, Academy of Managed Care Pharmacy 26^th Annual Meeting & Expo, 2014.

Jensen IS, Halbert RJ, Grosvenor A, Swartz E, Rossi G, Naoshy S, et al. Incorporating stakeholder input into budget impact models to compare stem cell mobilization strategies. Abstract PCN43, ISPOR 18th Annual International Meeting, 2013.

Kuan RK, Janssen R, Heyward W, Nordyke RJ. 2013. Cost-effectiveness of hepatitis B vaccination using HEPLISAV^TM in selected adults compared to Engerix-B^® vaccine. Vaccine 31(37):4024-32; doi: 10.1016/j.vaccine.2013.05.014. PMID: 23707166.

Olchanski N, McInnis-Myers M, Halseth M, Cyr PL, Bockstedt L, Goss TF, Howland RH. 2013. The economic burden of treatment-resistant depression. Clin Ther 35(4):512-522; doi: 10.1016/j.clinthera.2012.09.001.

Sacks NC. 2013. Avoidable costs in U.S. healthcare: The $200 billion opportunity from using medicines more responsibly. IMS Health, June.